Purpose: To evaluate the safety, MTD, pharmacokinetics/pharmacodynamics, and early clinical activity of ixabepilone given either weekly or every 3 weeks in combination with daily sunitinib in patients with advanced solid tumors.
Introduction
Tumor angiogenesis is a critical step in tumor progression and metastases and represents a clinically validated target for novel therapies (1) . Inhibition of the VEGF signaling pathway, by monoclonal antibodies and oral multitargeted receptor tyrosine kinase inhibitors (TKI), have shown improved disease control and clinical outcomes in patients with many malignancies, including colon, breast, brain, lung, ovarian, and renal cell carcinomas, among others (2-10). Unfortunately, antiangiogenic agents alone or in combination with chemotherapy are seldom curative due to the development of adaptive resistance (11, 12) .
A proposed mechanism by which tumors acquire resistance to anti-angiogenic agents is through increasing tumor hypoxia, which in turn leads to the activation of hypoxia-inducible pathways (13) . One of the most important pathways is mediated by hypoxia-inducible factor-1 a (HIF-1a), a transcription factor that mediates the expression of genes important for adaptation and survival under hypoxia (14, 15) . Therefore, tumors that become more hypoxic may become paradoxically more angiogenic, and in turn more resistant to antiangiogenic agents. For this reason, a combined strategy to simultaneously inhibit angiogenesis and HIF-mediated responses has the potential to prevent/delay the development of tumor resistance to angiogenesis inhibitors or restore sensitivity to antiangiogenic agents.
Several reports have demonstrated that antimicrotubule agents, such as epothilones and taxanes, have direct antiangiogenic effects that are independent of their antitumor activity (16, 17) . We have previously demonstrated that the sensitivity of endothelial cells to taxanes is in part due to increased drug uptake by endothelial cells compared with tumor cells, supporting the rationale for metronomic administration of microtubule-interfering agents (16) . Another mechanism by which antimicrotubule agents may affect angiogenesis is through downregulation of HIF-1a (18) . The exact mechanism by which microtubule-stabilizing agents exert their anti-HIF effects is still unclear but likely involves the inhibition of HIF-1a translation, following disruption of a functional microtubule network (14, 15, 18) .
Ixabepilone is a semisynthetic analogue of epothilone B, designed for optimal in vivo efficacy (17, 19) . Ixabepilone is known to be clinically active in treating many different solid tumors, including in patients with taxane-resistant tumors. Ixabepilone has been shown to have a greater synergistic antitumor effect than paclitaxel in preclinical in vivo breast, colon, lung, ovarian, and kidney cancer models when combined with the anti-VEGF mAb bevacizumab, or with sunitinib, an oral TKI with antiangiogenic activity through inhibition of VEGFRs, PDGFR-b, c-Kit, and FLT3 (17, 20) .
On the basis of these preclinical observations, we hypothesized that the combination of ixabepilone plus sunitinib would be clinically feasible and active in patients with advanced solid tumors. We also hypothesized that metronomic, that is, weekly ixabepilone would be more effective in the inhibition of tumor angiogenesis, leading to improved antitumor effects, compared with higher doses of ixabepilone every 3 weeks. Such an approach, utilizing ixabepilone in combination with sunitinib in cancer patients, has not previously been tested in clinical trials. We therefore conducted a phase I trial evaluating escalating doses of ixabepilone administered either weekly or every 3 weeks in conjunction with sunitinib for the treatment of patients with advanced refractory solid tumors. We also performed correlative studies to determine the impact of this combination on angiogenesis biomarkers.
Patients and Methods

Patient population
This was a phase I, open-label dose-escalation study to evaluate the safety and tolerability of two different dose schedules of ixabepilone (weekly and every 3 weeks), in combination with a fixed dose of sunitinib in patients with solid tumors previously treated with up to 4 prior systemic therapy regimens. The study was conducted from December, 2008, to August, 2013, at the University of Miami Sylvester Comprehensive Cancer Center (UM-SCCC; Miami, FL). All patients were adults ages >18 years with an advanced, refractory nonhematologic malignancy that had progressed on standard therapy. In addition, Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, absolute neutrophil count (ANC) > 1,500; hemoglobin > 9 g/dL; platelets > 100,000/mc; total bilirubin < upper limit of normal (ULN); AST/ALT < ULN (<5 ULN in patients with documented liver metastases); alkaline phosphatase: <2.5 ULN (<5 ULN in patients with known liver metastases); serum creatinine < 1.5 ULN; and a urine protein/creatinine ratio < 1, or < 1þ protein in the urine. Patients were ineligible if they had received more than 4 prior lines of systemic therapy for metastatic disease or if they had received prior cancer therapy <28 days before the first study day. Other exclusion criteria included (i) prior ixabepilone; (ii) active treatment with a cytochrome P450 (CYP) 3A4 enzyme-inducing or enzyme-inhibitor medication; (iii) cardiovascular disease (congestive heart failure > New York Heart Association class II, uncontrolled arrhythmia, recent myocardial infarction, or cerebrovascular accident), other uncontrolled concurrent disease (e.g., diabetes, active infection), or immunosuppressive therapy; (iv) uncontrolled hypertension, defined as a blood pressure of >150 mm Hg systolic and/or >90 mm Hg diastolic on medications; (v) prior history of an abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess 28 days for date of enrollment; and (vi) motor or sensory neuropathy ! grade II at study entry. Patients with symptomatic/untreated central nervous system (CNS) or leptomeningeal metastases were also ineligible. However, patients with known CNS metastases were eligible, provided that CNS metastases had been (i) appropriately treated with whole brain radiotherapy, radiosurgery (gamma knife, LIN-AC, or equivalent), or resection as deemed appropriate by the treating physician (patients who had surgical resection of CNS metastases or brain biopsy within 3 months prior to day 1 were excluded); (ii) had no ongoing requirement for dexamethasone; and (iii) had no evidence of progression or hemorrhage after treatment (brain imaging study within 4 weeks of treatment start).
The study was conducted in full conformance as outlined by UM-SCCC Institutional Review Board. The trial followed Good Clinical Practice Guidelines as outlined in Title 21 of the Code of Federal Regulations. Accordingly, investigators obtained informed consent from each participant. This study was registered as NCT00884676.
Study design
A standard 3 þ 3 dose escalation design was utilized, taking into account dose-limiting toxicity (DLT) occurring in the first cycle (toxicity observation period), following treatment administration. Two different dose schedules for ixabepilone were evaluated (Fig. 1) . In schedule A, ixabepilone was administered weekly intravenously over 1 hour, 3 weeks out of 4 (cycle length of 4 weeks AE 3 days). In schedule B, ixabepilone was administered once every 3 weeks intravenously over 3 hours (cycle length of 3 weeks AE 3 days). In both schedules, daily sunitinib (37.5 mg) was administered starting on day 8 of cycle 1 (days 8-28 and 8-21 for schedules A and B, respectively). For subsequent cycles, sunitinib was started on day 1 in combination with ixabepilone. Patients were assigned to either schedule A or B, and no crossover was allowed. The starting dose of weekly ixabepilone in schedule A was 7.5 mg/m 2 , followed by dose escalation to 15 and 20 mg/m 2 . For schedule B (ixabepilone given every 3 weeks), the starting dose level was 20 mg/m 2 , escalating to 30 and 40 mg/m 2 , respectively ( Fig. 1) . Sunitinib was administered in both schedules at a daily
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Although antiangiogenic therapies represent clinically beneficial therapeutic options for a number of solid tumors, the development of resistance to these agents constitutes a major clinical challenge. Ixabepilone and other microtubule-interfering agents exert direct and indirect anti-angiogenic effects, especially when given in a metronomic fashion, and may be synergistic when combined with anti-VEGF agents. In this study, we show the feasibility and safety profile of the combination of either metronomic (weekly) or standard (every 3 weeks) ixabepilone with daily, low-dose sunitinib in patients with refractory solid tumors. Our results demonstrate promising clinical activity, especially in patients with refractory colorectal cancer. The metronomic ixabepilone schedule was associated with a greater reduction in tumor size, and with measurable changes in angiogenesis biomarkers that correlated with clinical benefit. Our clinical and pharmacodynamic results are encouraging and warrant further evaluation and validation in larger clinical trials.
fixed dose of 37.5 mg. Radiographic imaging was performed every other cycle in schedule A patients (every 8 weeks) and every third cycle in schedule B patients (every 9 weeks). The treatment was continued until disease progression, unacceptable toxicity, patient withdrawal, or decision by the investigator.
A DLT was defined in this protocol as an adverse event (AE) that was attributed (definitely, probably, or possibly) to treatment in the first four weeks for schedule A and the first 3 weeks for schedule B of combination therapy, during the dose escalation portion, and meeting any one of the following criteria: (i) grade IV ANC for >5 days; (ii) grade IV anemia or thrombocytopenia of any duration; (iii) grade III thrombocytopenia with bleeding; (iv) increase in serum creatinine >2 times pretreatment levels; (v) any grade III or greater toxicity, excluding fatigue, alopecia, or grade III hypertension that is well controlled with oral medication; (vi) grade III nausea, vomiting, or diarrhea despite maximal supportive treatment; (vii) any toxicity that causes dose delay of >2 weeks of the intended next dose; and (viii) any toxicity that requires missing more than one dose of ixabepilone or more than two doses of sunitinib in the first cycle. Following standard dose escalation rules, the MTD/phase II-recommended doses of ixabepilone and sunitinib for each schedule (A and B) were established as the highest dose level tested, for which no more than 1 of 6 patients in the dose-escalation phase experienced a DLT. Once the MTDs for schedules A and B were reached, an expansion cohort was opened with a goal to enroll up to 10 subjects in schedule A or B to further characterize the AE profile, as well as preliminary efficacy of the combination.
Pharmacokinetics
Sunitinib. Blood samples were collected into ethylenediaminetetraacetic acid (EDTA) vacutainer tubes at different timepoints for each schedule. Patients enrolled into schedule A had blood collected at the following times: cycle 1, days 1, 8, 15, and 22; cycle 2, days 1 and 15 prior to receiving sunitinib. Patients enrolled into schedule B had blood collected at the following timepoints: cycle 1, days 8 and 15 prior to receiving sunitinib; cycle 2, day 1 prior to sunitinib and 0.5, 1, 2, 3, 4, 6, 8, 24, and 48 hours postsunitinib; cycle 2, days 8 and 15; and cycle 3, day 1 prior to sunitinib. Blood samples were centrifuged at 4 C for 10 minutes; plasma was separated, split into two 1.5 mL Nalgene cryovials, and stored at À70 C, protected from light until analysis. Plasma concentrations of SU11248 and SU12662 were determined by means of a validated and sensitive LC/MS-MS method (SAP.793), with a lower detection limit of 0.099 ng/mL for sunitinib and 0.088 ng/mL for its metabolite, SU12662 (21).
Ixabepilone. Blood samples drawn from a peripheral vein were collected into EDTA tubes. In schedule A, samples were collected during cycle 1 before and at 0.5 hour after the start of the ixabepilone infusion, at the end of the 1-hour infusion, at 0.25, 0.5, 1, 2, 3, 5, 7, 23, and 47 hours after the end of infusion, and before the next infusion 7, 14, and 21 days later. This was repeated for cycle 2 day 1. Predose sampling was also collected before cycle 2 day 15 and cycle 3 day 1. In schedule B, samples were collected at the following time points: (i) pretreatment; (ii) 0.5, 1, and 2 hours after the start of ixabepilone infusion; (iii) postixabepilone infusion: upon completion, 1, 3, 5, 21, 45, and 165 hours postinfusion; and (iv) day 15 predose. This was repeated in cycle 2. Predose sampling was also collected before cycle 3 day 1. Each sample was centrifuged at approximately 1,000 Â g at 4 C for 10 minutes, and the resulting plasma was stored at À20 C or colder until analyzed. Ixabepilone concentrations were quantitated by LC/MS-MS based on a previously published assay (21, 22) . Modifications were as follows. The LC system consisted of an Agilent 1200 SL Autosampler and Binary Pump, a YMC-Pack ODS-AQ (3 mm, 100 mm x 2 mm) column, (YMC America, Inc), and an isocratic mobile phase of acetonitrile/water (70/30, v/v) with 10 mmol/L ammonium acetate, pH 5.0, pumped at a flow rate of 0.3 mL/minute. The overall run time was 2.5 minutes. Two aliquots of 50 mL of plasma, 500 mL of acetonitrile with internal standard (40 ng/mL BMS-212188) were added. After vortexing and centrifugation, 100 mL of supernatant was transferred to autosampler vials, followed by injection of 5 mL. This assay was accurate (within 10%) and precise CV% (within 14%) over a range of 1 to 1,000 ng/mL.
The maximum plasma concentration (C max ) and the time to reach it (T max ) were determined by visual inspection of the plasma concentration versus time data. Other pharmacokinetic parameters were calculated noncompartmentally using PK Solutions 2.0 (Summit Research Services; www.summitPK.com). Pharmacokinetic parameters between days were compared by nonparametric two-tailed Wilcoxon exact signed rank test as implemented by IBM SPSS Statistics version 22.
Biomarker studies. Correlative biomarker studies consisted of determination of circulating endothelial cells (CEC), circulating endothelial progenitor cells (CEPC), and plasma angiogenic activity (PAA). These studies were performed at baseline cytometry was performed using a FACSCalibur flow cytometer, and the analysis was performed using CellQuest Software, as reported previously (23, 24) . PAA is a functional bioassay that quantitatively assesses the ability of patient plasma to induce (or inhibit) in vitro endothelial cell proliferation using a colorimetric assay, as described previously (16, 25) . Briefly, 4 Â 10 3 HUVECs (Lonza), suspended in endothelial basal medium (Lonza) supplemented with 1% FBS, were seeded into each well of a 96-well microtiter plate and exposed to patient plasma, which was separated from citrated tubes (5-7 mL of blood) obtained from patients at baseline (pretreatment) and after cycle 1. To avoid clot formation during the assay, heparin (5 U/mL) was added to all plasma samples before exposure to endothelial cells. Treated and control (no patient plasma) cells were incubated at 37 C for 72 hours. At the end of this period, WST-1 (10 mL, Roche) was added to each well and incubated at 37 C for 3 hours, and absorbance at 450 nm was determined using a Microplate Reader (Bio-Rad). The experiments were performed in triplicate. Baseline PAA values were normalized (percentage) to untreated control cells (no patient plasma) and displayed as dot plots, where each dot represents the average (from triplicates) value for an individual patient. Changes in PAA from baseline to after cycle 1 are presented as percentage changes compared with the baseline.
Results from the biomarker studies (PAA, CEC, and CEPC) at baseline and their changes postbaseline were analyzed (in an exploratory manner) in the context of ixabepilone schedule (A vs. B), as well as clinical outcomes, such as the best response (by RECIST 1.1) or prolonged benefit (patients on study for more than 6 or 7 cycles).
Statistical Analysis
Patient demographic characteristics (age and race/ethnicity), ECOG performance status, and histology were summarized using descriptive statistics; counts and percentages, range, and median. Toxicities were tabulated according to type and grade. In patients with measurable disease, response was evaluated using the RECIST criteria. Clinical benefit rates [complete response (CR), partial response (PR), or stable disease (SD)] were estimated according to the percentage of patients achieving the response criterion and the corresponding 95% confidence interval (CI) based on the exact binomial method. Maximum percent reduction of target lesions by schedule was tested using Student t test. In correlative studies, two nonparametric tests were used: Wilcoxon rank sum test for comparing two groups (e.g., dose schedules, response, etc.) and KruskalWallis test for comparing more than two groups. Several jittered scatter plots were shown for the illustration. For change between baseline and cycle 2, profile lines between two time points were shown. Statistical analysis was performed by SAS version 9.2 and R.
Results
Patient enrollment and overview of study treatments
A total of 46 patients signed informed consent, of which 36 met all eligibility criteria, and were enrolled in the study. Of those, two eligible patients never received treatment as they elected not to proceed with the treatment. Relevant characteristics of the 34 patients who received treatment are described in Table 1 . The median age was 59 years (range, 25-78 years. Approximately half of all enrolled patients had metastatic colorectal cancer, 47% (8/17) of which had KRAS mutations. The second most common malignancy among study participants was pancreatic cancer (11.9%). The vast majority of patients had an ECOG performance status of 0 (44%) or 1 (53%), with only 1 patient with a baseline ECOG performance status of 2. Most patients had received prior therapies in the metastatic setting, with 3 (8.8%), 11 (32.4%), and 20 (58.8%) patients having received 0 to 1, 2, and >2 prior lines of systemic therapy, respectively.
Dose escalation and safety
All treated patients (n ¼ 34) were considered evaluable for toxicity evaluation. Of those, 28 patients were in the dose-escalation phase, where dose-escalation rules were followed, and 6 patients were in the dose-expansion phase, where toxicity was assessed, but dose-escalation rules were not applicable. Five patients in the dose-escalation portion did not complete one cycle of therapy (reasons other than drug-related toxicity) and were replaced as per protocol guidelines. Coadministration of ixabepilone and sunitinib was fairly well tolerated. Three DLTs, as defined by the protocol, were observed in cycle 1 during the dose-escalation phase. In schedule A, 1 DLT was observed in schedule 3A [grade III deep venous thrombosis (DVT)], leading to expansion to 6 patients, where no other DLTs were observed. In schedule 3B, 2 DLTs were observed in 6 patients (grade IV mucositis and grade IV prolonged neutropenia). Therefore, dose level 3B was closed, and 3 more patients were enrolled in schedule 2B, without DLTs observed. Overall, the median number of chemotherapy cycles that were administered per patient was 3 (range 2-11 cycles).
A total of 686 AEs were observed overall, 609 (88%) of which were limited to grade I-II. The most common treatment-related AE (Table 2A) were five hematologic AEs (leukopenia, neutropenia, lymphopenia, anemia, and thrombocytopenia) and two nonhematologic AE (fatigue and hyperglycemia). Peripheral neuropathy was mostly grade I/II and occurred in 18 subjects (13/20 patients in schedule A and 5/14 patients in schedule B) and grade III in one subject (schedule B). When organized by ixabepilone dose schedule, there were 53 and 24 grade III-IV AEs, primarily hematologic toxicities, with schedule A and schedule B, respectively. This translated into eleven patients (33%) overall in the study that experienced a grade III-IV AE.
Efficacy
Twenty-seven study participants were evaluable for response. A best tumor response of PR was observed in 4 patients (15%), whereas SD was observed in 13 patients (48%; Fig. 2A) . Of the 4 patients with a PR, 3 (2 colorectal and one breast cancer) patients were in schedule A, and one patient (metastatic bladder cancer) was in schedule B. A greater overall reduction in tumor size was noted with weekly ixabepilone than the every 3-week dosing schedule (Fig. 2B) . Approximately half of all enrolled patients had metastatic colorectal cancer, with most of them having KRAS mutations. In this subset of patients, the overall clinical benefit rate (CR, PR, or SD) was 53% (9/17 patients).
Pharmacokinetics
Serial pharmacokinetic data for ixabepilone were analyzed for schedules 2A (n ¼ 4), 2B (n ¼ 4), and 3A (n ¼ 7) only. For the other schedules, there were not sufficient data to analyze. Pharmacokinetic parameters of ixabepilone alone, as well as the effect of sunitinib coadministration, are presented in Table 3 . Ixabepilone is metabolized by CYP3A4 and has previously been shown to have clinically significant interactions with strong CYP3A4 inducers and inhibitors (26) . On the other hand, sunitinib is also metabolized by CYP3A4, but its metabolism has not been shown to be affected by strong CYP3A4 inducers and/or inhibitors. We therefore hypothesized that ixabepilone pharmacokinetics were more likely to be affected by sunitinib than vice versa, and therefore, the pharmacokinetic design was aimed at primarily evaluating ixabepilone pharmacokinetics. Patients served as their own controls by first administering ixabepilone alone, followed by ixabepilone plus sunitinib to better quantify the impact of sunitinib on ixabepilone metabolism. Pharmacokinetic analysis demonstrated a significant increase in the half-life of ixabepilone, a corresponding significant decrease in clearance, and a trend towards an increased C max with weekly, that is, schedule A, but not every 3 week ixabepilone (Table 3) .
Serial pharmacokinetic data for sunitinib were analyzed for schedule 2B (n ¼ 5), as this was the recommended phase 2 dose (RP2D). For schedules 2A and 2B, the AUC for sunitinib was calculated (Table 3) . Large interpatient variability was observed. Sunitinib (SU011248) is primarily metabolized by CYP3A4, producing its primary metabolite, SU012662, which is further metabolized by CYP3A4 (27) . In this study, we measured blood levels of both the sunitinib parent compound and its main metabolite in patients receiving a dose of 37.5 mg orally once daily in combination with intravenous ixabepilone at 7.5 to 20 mg i.v. over 1 hour weekly Â 3 weeks every 4 weeks or at 20 to 30 mg i.v. over 3 hours given every 3 weeks. Large interpatient variability was observed (data not shown). Serial pharmacokinetic data for sunitinib are shown in Table 3 . There was no observed effect of ixabepilone on sunitinib pharmacokinetic parameters of T max , C max , AUC, and t 1/2 . As previously reported elsewhere (26) , there was SU011248/SU012662 accumulation (C max and AUC), with continuous dosing compared with single dosing, which was not affected by concurrent administration of ixabepilone in either weekly or every 3 week schedules.
Correlative studies
Twenty-six (of 27) patients evaluable for efficacy had adequate samples for determination of PAA, and 20 (of 27) patients evaluable for efficacy had adequate samples for determination of CEC/ CEPCs. At baseline (pretreatment), no significant differences were observed in CEC or CEPC numbers between patients in schedule A or B, while PAA was significantly higher (P ¼ 0.035) in patients in schedule A compared while schedule B (Supplementary Fig. S1 ). Patients receiving weekly ixabepilone (schedule A), who achieved PR or SD as best response, had significantly higher baseline PAA compared with nonresponding patients (Fig. 3A) . Likewise, patients assigned to schedule A (but not schedule B) with a prolonged clinical benefit (PR or SD lasting 7 cycles or more) had significantly higher baseline PAA (P ¼ 0.042; Fig. 3B ). No significant correlations were observed between CEC or CEPC levels at baseline and clinical benefit in schedule A or B patients (not shown). Subjects who remained in study for 6 cycles or more had a trend (P ¼ 0.129) toward higher baseline CEC levels (Fig. 3C) .
PAA significantly decreased as a result of the treatment in patients in the metronomic ixabepilone (schedule A) group (P ¼ 0.043), whereas it increased from baseline levels in patients treated with ixabepilone given every 3 weeks (Fig. 3D) . Patients in schedule A (but not schedule B), whose best response was PR/SD, had a nonstatistically significant trend toward a decrease in PAA at cycle 2 ( Fig. 3E ) compared with patients who progressed. No significant associations were observed between postbaseline changes in CEC levels and clinical outcomes (not shown). Patients in schedule B, who had PR/SD as best response, had a significant increase in CEPC levels compared with nonresponding patients (Fig. 3F) .
Discussion
The objectives of this phase I study were to determine the safety and feasibility of either metronomic (schedule A, weekly) or Table 3 . Ixabepilone and sunitinib noncompartmental pharmacokinetic parameters
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AUC obs (ng a h/mL) Leukopenia  77  60  48  11  1  17  13  3  1  Neutropenia  48  37  26  8  3  11  5  3  3  Lymphopenia  76  60  52  8  0  16  12  4  0  Anemia  57  40  38  2  0  17  15  2  0  Thrombocytopenia  41  32  29  3  0  9  8  1  0  Nonhematologic  Nausea  25  15  15  0  0  10  8  2  0  Vomiting  19  14  14  0  0  5  4  1  0  Diarrhea  34  25 standard (schedule B, every 3 week) ixabepilone in combination with sunitinib in patients with advanced solid tumors; and to assess, in an exploratory manner, the differential effects of metronomic versus standard ixabepilone on angiogenesis biomarkers and their association with clinical activity. Of the 36 enrolled patients, 34 were evaluable for toxicity, and 27 patients were evaluable for clinical efficacy. The results described in this study demonstrate that the combination of ixabepilone and sunitinib was feasible, had an acceptable toxicity profile, and demonstrated encouraging clinical activity in heavily pretreated patients with advanced solid tumors, particularly in patients with metastatic colorectal cancer.
Coadministration of sunitinib and ixabepilone was relatively well tolerated, and the AE profile was consistent with the known toxicity profiles of each agent. Irrespective of ixabepilone dose schedule, the three most common hematologic toxicities (all grades) were leukopenia, lymphopenia, and anemia; whereas three most commonly observed nonhematologic toxicities (all grades) were hyperglycemia, fatigue, and diarrhea. For both weekly and every 3 week ixabepilone dose schedules, the most commonly observed grade III-IV toxicity was neutropenia, although more frequently observed in the former than the latter. On the basis of the dose-escalation rules, the MTD for weekly ixabepilone (schedule A) was 20 mg/m 2 , with sunitinib 37.5 mg daily. For every 3 week ixabepilone in combination with 37.5 mg of sunitinib daily, (schedule B) the MTD was 30 mg/m 2 . During the dose-escalation phase, the only observed DLT in schedule 3A was a DVT, whereas in schedule 3B, grade IV mucositis and grade IV prolonged neutropenia were the observed DLTs.
Pharmacokinetic analysis revealed that coadministration of sunitinib with ixabepilone on a weekly (but not every 3 week) schedule was associated with a significant increase in the half-life and significant decrease in the clearance of ixabepilone. This suggests that coadministration of sunitinib could potentially lead to an increase in ixabepilone-specific toxicities and therefore may require dose reduction. However, in this study, toxicities with weekly ixabepilone and sunitinib were not excessive.
The rationale for this clinical trial was predicated on previously published preclinical studies, which indicated a synergistic interaction with sunitinib and ixabepilone on inhibition of tumor neoangiogenesis, as sunitinib may enhance delivery of ixabepilone to the tumor by inducing vascular normalization (17, 20) . We also hypothesized that ixabepilone given at a lower and more continuous (metronomic) schedule would be associated with increased antiangiogenic effects in combination with sunitinib, which may translate into better clinical antitumor effects. We indeed found that weekly administration of ixabepilone had a higher number of responses than the every 3-week schedule when combined with sunitinib. Interestingly, we found a rather high proportion of patients with metastatic colorectal, cancer most of which had KRAS mutations that had clinical benefit to treatment with sunitinib and ixabepilone. This is particularly intriguing since taxanes as single agents are not typically known to have activity in colon cancer, and a prior phase II study with sunitinib did not find any activity in patients with metastatic colorectal cancer who had progressed on standard therapy (28) . The responses observed in schedule A occurred mostly in dose level 2 (2 PRs), and dose level 1 (1 PR), whereas the benefit from dose level 3A was mostly SD. For this reason, even though dose level 3A was defined as the MTD, based on tolerability and clinical activity, we propose dose level 2A (15 mg/m 2 of ixabepilone) and 37.5 mg/day of sunitinib as the phase II-recommended dose. The phase II-recommended dose for schedule B is 30 mg/m 2 of ixabepilone (dose level 2B) and 37.5 mg/day of sunitinib.
Among the biomarker studies performed in this trial (PAA, CECs, and CEPCs), statistically significant clinical-biologic correlations were observed only with PAA. PAA is a functional assay that measures the biologic effects of the patient plasma on endothelial cell proliferation and its changes before and during treatment (25) . As the angiogenic state of a patient is regulated by a dynamic balance between endogenous angiogenesis activators and inhibitors, measuring the effects of patient plasma on endothelial cell function may reflect changes in the patient's overall angiogenic balance, and therefore, may offer an advantage over assays that measure individual biomarkers, like VEGF, bFGF, IL8, etc. A statistically significant association was found between clinical benefit (PR/SD and benefit for !7 cycles) and higher PAA at baseline in patients treated with metronomic ixabepilone. In addition, metronomic, but not every 3 week, ixabepilone induced a statistically significant reduction in PAA in patients treated in schedule A, but not schedule B. Schedule B patients actually had nonstatistically significant increase in PAA at cycle 2 compared with baseline. These observations suggest that patients with a higher plasma angiogenic state may benefit from lower dose, weekly ixabepilone, compared with patients in the every 3-week schedule. The correlation between changes in the plasma angiogenic activity and clinical benefit in patients in the metronomic ixabepilone group may suggest that PAA may prove a useful angiogenesis biomarker that can be used to monitor changes in the patient's angiogenic state before and during treatment. However, due to the small patient numbers in this phase I trial, and the exploratory nature of the biomarker studies, the above results should be considered hypothesis generating and need to be further validated in larger trials using other antiangiogenic strategies.
In summary, this study demonstrates the feasibility, safety, and early clinical activity of the combination of sunitinib and ixabepilone given in two different dosing schedules. The observation that weekly ixabepilone was associated with considerable clinical activity, and with a reduction in angiogenesis biomarkers, is particularly promising. Further confirmation of the clinical activity of this combination, especially in patients with advanced colorectal cancer, and validation of PAA as a potentially useful angiogenesis biomarker is warranted. 
